Kerasal Nail Gains Extended Distribution Deal For China

Moberg Pharma AB announced that Menarini Asia-Pacific, a member of the Menarini Group, has been granted the exclusive rights to market and sell Kerasal Nail in China.

The companies now intend to seek marketing authorization for the product in the Chinese market.

Kerasal Nail is a non-prescription product for the treatment of discolored and deformed nails resulting from fungal infection or psoriasis, with a claimed mechanism of action that generates visible improvements within 2-4 weeks of treatment.

The extended distribution agreement builds on an existing collaboration between the two company groups, which resulted in a successful launch of the product in Italy.

You May Also Like

Leave a Reply

Your email address will not be published.